

Transforming Patients' Lives Through Science



Bristol Myers Squibb (BMS) is a global biopharmaceutical company dedicated to researching, developing and delivering innovative medicines that help patients overcome serious diseases. For 100 years, our team in Canada, has passionately and precisely worked to bring life-saving medicines to Canadians across the country, and we continue to transform patients' lives through lifesaving, innovative medicines in oncology, hematology, immunology, neuroscience, and cardiovascular disease.


BMS in Canada

Established in 1925	Head office in Montreal	170+ Employees
Top 10 Biopharma	Working with 30+ patient advocacy associations	



Our Innovation Engine

With one of the most diverse and promising global pipelines in the industry, BMS is accelerating breakthrough science for patients with serious unmet needs.



Canada			Globally
 Close to \$45M invested in research and development	 1st Immuno-oncology medicine in Canada and leader in personalized medicine	 Top 5 major pharmaceutical companies in the number of active trials in Canada	 \$11.2B industry-leading annual research and development investment
 2 Prix Galien awards	 140 clinical studies undergone in 2025	 BMS Canada is involved in approximately 70% of priority global trials and 164 total trials, representing more than 1,500 Canadian patients	 44 therapies in development across 40 disease areas

Our culture

Diverse and inclusive workforce representing Canadian values.
4 People and Business Resource Groups

Committed to gender representation and advancing the careers of women:

Recognized with Women in Governance gender parity certifications for four years running



47% women in senior management positions

A legacy of innovation, a future of hope for patients.
Transforming patients' lives through science. Learn more at bms.com/ca